Respiratory delivery of favipiravir-tocilizumab combination through mucoadhesive protein-lipidic nanovesicles: prospective therapeutics against COVID-19.

Virusdisease · 2021 · PMC7966910 · PMID 33748347

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

The drug achieves its maximum plasma concentration at 2 h following administration [ 29 ] Evidence from a proof-of-concept trial with favipiravir has shown a positive trend toward survival in an outbreak of Ebola in West Africa during 2014–2015 [ 30 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.